Thermo Fisher Scientific: stocks, financial statements

Disable ads for free
Dividends News
Favorites

Thermo Fisher Scientific, Inc. engages in the provision of analytical instruments, equipment, reagents and consumables, software and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions; Analytical Instruments; Specialty Diagnostics; and Laboratory Products and Services. The Life Sciences Solutions segment comprises of portfolio of reagents, instruments, and consumables used in biological and medical research, discovery and production of new drugs, and vaccines as well as diagnosis of disease. The Analytical Instruments segment offers instruments, consumables, software, and services that are used for a range of applications in the laboratory, on the production line, and in the field. The Specialty Diagnostics segment gives diagnostic test kits, reagents, culture media, instruments, and associated products used to increase the speed and accuracy of diagnoses. The Laboratory Products and Services segment involves in providing everything needed for the laboratory, including a combination of self-manufactured and sourced products for customers in research, academic, government, industrial, and healthcare settings. The company was founded on October 11, 1960 and is headquartered in Waltham, MA.

  • TMO Ticker
  • NYSE Exchange
  • 70,000 Employees
5 rated
  • $474.62, $-2.58 (-0.54%) Previous Close
  • 1,439,556 Previous Volume
  • $255.00 / $527.66 52 week low / high
  • -10.05% Percent off 52 week high
  • 2020-12-04 Updated
  • 0.18% Dividend Yield (trailing)
  • 0.19% Dividend Yield (forward)
  • 0 Public float
  • 396,335,191 Outstanding shares
  • 38.76 P/E
  • 189.13 B Market Cap
Disable ads for free

Financial statements — Thermo Fisher Scientific

The information is not 100% up-to-date. There may be errors or missing information. Some information is often missing, and, although there are almost no errors, I can't rule them out. Right now, I'm looking for a supplier of high-quality information, but so far what I'm finding is expensive (about $2000 a year). You can help my project here.
19 ← 15 2019 2018 2017 2016 2015
Total Revenue
26B 24B 21B 18B 17B
Cost Of Revenue
15B 13B 11B 9.7B 9.1B
Gross Profit
10B 11B 9.7B 8.6B 7.8B
Research and Development
1B 970M 890M 750M 690M
Selling General and Admin
4.9B 6B 5.4B 4.9B 4.6B
Operating Expense
21B 20B 18B 15B 14B
Operating Income
4.2B 3.9B 3.3B 2.9B 2.5B
Other Income Expense Net
-110M -610M -840M -840M -560M
EBIT
4.2B 3.9B 3.3B 2.9B 2.5B
Interest Income
680M 670M 590M 470M 410M
Pretax Income
4.1B 3.3B 2.4B 2B 1.9B
Income Tax
370M 320M 200M -1.4M -44M
Minority Interest
0 0 0 0 0
Net Income
3.7B 2.9B 2.2B 2B 2B
Net Income Basic
3.7B 2.9B 2.2B 2B 2B
19 ← 15 2019 2018 2017 2016 2015
Current cash
2.4B 2.1B 1.4B 790M 450M
Short term investments
3M 10M 16M 14M
Receivables
5B 4.6B 3.9B 3B 2.5B
Inventory
3.4B 3B 3B 2.2B 2B
Other current assets
1.2B 910M 770M 960M 740M
Current assets
12B 11B 9.4B 7B 5.7B
Long term investments
35M 38M 34M 37M 39M
Property plant equipment
5.4B 4.2B 4B 2.6B 2.4B
Goodwill
26B 25B 25B 21B 19B
Intangible assets
14B 15B 17B 14B 13B
Other assets
1.3B 1.1B 1.2B 970M 1.1B
Total assets
58B 56B 57B 46B 41B
Accounts payable
1.9B 1.6B 1.4B 930M 820M
Current long term debt
680M 580M 1.2B 300M 1B
Other current liabilities
3.4B 3.3B 3.5B 2.5B 2.1B
Total current liabilities
6.2B 6.1B 7B 4.9B 4.1B
Long term debt
18B 18B 19B 15B 11B
Other liabilities
2.7B 2.5B 2.6B 1.6B 1.3B
Minority Interest
0 0 0 0 0
Total Liabilities
29B 29B 31B 24B 20B
Common stock
430M 430M 400M 390M 400M
Retained earning
22B 19B 16B 14B 12B
Treasury stock
1.1M 1.1M 930K 950K 1M
Capital surplus
15B 15B 14B 12B 12B
Shareholder equity
30B 28B 25B 22B 21B
Net tangible assets
-47B -49B -51B -43B -36B
19 ← 15 2019 2018 2017 2016 2015
Net Income
3.7B 2.9B 2.2B 2B 2B
Depreciation
2.3B 2.3B 2B 1.8B 1.7B
Changes in receivables
-360M -720M -830M -500M
Changes in inventories
-460M -320M -81M 98M -140M
Cash change
310M 760M 550M 330M -890M
Cash flow
5B 4.5B 4B 3.2B 2.8B
Capital expenditures
-930M -760M -510M -440M -420M
Investments
22M 80M 18M
Investing activity other
-9M -24M -5.3M -5.8M
Total investing cash flows
-1.5B -1.3B -7.7B -5.5B -1.1B
Dividends paid
-300M -270M -240M -240M -240M
Net borrowings
-1.4B -1.6B 3B 4.2B -1.9B
Other financing cash flows
-69M -51M -3M 40M 58M
Cash flow financing
-3.1B -2.2B 3.9B 2.9B -2.5B
Exchange rate effect
-63M -300M 420M -150M -130M
Disable ads for free
Disable ads for free